business

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases - Eli Lilly

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

Source:Lilly.com
Published:
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases - Eli Lilly
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly's established capabilities in inflammatory… [+12888 chars]

Related News